TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of the Mckenzie Method in Patients With Chronic Non-Specific Low Back Pain: A Randomized Placebo-Controlled Trial
Brief Summary: The purpose of this study is to assess the efficacy of the McKenzie method in patients with chronic non-specific low back.


Options:
A: Arm Label: Individual Cognitive Functional Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Cognitive Functional Therapy | Arm Label: Group Exercise Classes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Exercise Classes | Intervention Type: BEHAVIORAL; Name: Individual Cognitive Functional Therapy; Assigned to Arm(s): Individual Cognitive Functional Therapy | Intervention Type: BEHAVIORAL; Name: Group Exercise Classes; Assigned to Arm(s): Group Exercise Classes
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: McKenzie method; Type: EXPERIMENTAL; Interventions: Other: McKenzie method | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: McKenzie method; Assigned to Arm(s): McKenzie method
C: Intervention Type: BEHAVIORAL; Name: Supervised Nordic Walking; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Unsupervised Nordic Walking; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Advice to stay active; Assigned to Arm(s): N/A
D: Arm Label: Exercise and advise to stay active; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Rest and use of flexible lumbar belt; Type: EXPERIMENTAL; Interventions: Other: Restitution | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise and advise to stay active | Intervention Type: OTHER; Name: Restitution; Assigned to Arm(s): Rest and use of flexible lumbar belt

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: THE EFFECT OF WALKING MEDITATION TRAINING ON GLYCEMIC CONTROL AND VASCULAR FUNCTION IN PATIENTS WITH TYPE 2 DIABETES
Brief Summary: Walking Meditation training would yield more favorable adaptations than walking alone in improving glycemic control and vascular function in patients with type 2 diabetes.


Options:
A: Arm Label: Distress management; Type: EXPERIMENTAL; Interventions: Behavioral: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives; Assigned to Arm(s): Distress management
B: Arm Label: ACT-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACT-based intervention, Behavioral: usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: ACT-based intervention; Assigned to Arm(s): ACT-based intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): ACT-based intervention, Usual care
C: Arm Label: Standard lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard lifestyle intervention | Arm Label: Mind-body lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mind-body lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Mind-body lifestyle intervention; Assigned to Arm(s): Mind-body lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Standard lifestyle intervention; Assigned to Arm(s): Standard lifestyle intervention
D: Arm Label: Walking meditation & Walking; Type: EXPERIMENTAL; Interventions: Other: Walking Meditation, Other: Walking | Arm Label: Walking meditation & No exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Walking Meditation, Other: No exercise | Intervention Type: OTHER; Name: Walking Meditation; Assigned to Arm(s): Walking meditation & No exercise, Walking meditation & Walking | Intervention Type: OTHER; Name: Walking; Assigned to Arm(s): Walking meditation & Walking | Intervention Type: OTHER; Name: No exercise; Assigned to Arm(s): Walking meditation & No exercise

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru
Brief Summary: This is a Phase 1 study to assess the safety and tolerability of Lactobacillus reuteri (Lr) strain DSM 17938 in healthy children in Peru. It is a preliminary study in support of a clinical trial to assess safety and efficacy of L. reuteri for treatment of pediatric diarrhea in Peru.


Options:
A: Arm Label: Group I; Type: N/A; Interventions: N/A | Arm Label: Group II; Type: N/A; Interventions: N/A
B: Arm Label: Lactobacillus; Type: EXPERIMENTAL; Interventions: Biological: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Lactobacillus reuteri; Assigned to Arm(s): Lactobacillus | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Test group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic yogurt | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic yogurt; Assigned to Arm(s): Test group | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Cessation Rates in Smokers Using Personal Vaporizers: A Prospective 6-month Pilot Study
Brief Summary: E-cigarettes are proving to be an attractive long-term alternative to conventional cigarettes. Although they may also help smokers to remain abstinent during their quit attempt, recent clinical trials with first generation e-cigarettes have shown only modest quit rates. Second generation devices may result in much higher quit rates. Their efficacy and safety in long-term smoking cessation and/or smoking reduction studies have never been investigated.

In this prospective proof-of-concept study we monitored modifications in smoking habits of 50 regular smokers (unwilling to quit) who were asked to switch to a second generation device focusing on smoking reduction and smoking abstinence. Study participants were invited to attend a total of five study visits: at baseline, week-4, week-8, week-12 and week-24. Product usage, number of cigarettes smoked, and exhaled carbon monoxide (eCO) levels were measured at each visit. Smoking reduction and abstinence rates were calculated. Adverse events and participants' opinions of these products were also reviewed.


Options:
A: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
B: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
D: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Cessation Rates in Smokers Using Personal Vaporizers: A Prospective 6-month Pilot Study
Brief Summary: E-cigarettes are proving to be an attractive long-term alternative to conventional cigarettes. Although they may also help smokers to remain abstinent during their quit attempt, recent clinical trials with first generation e-cigarettes have shown only modest quit rates. Second generation devices may result in much higher quit rates. Their efficacy and safety in long-term smoking cessation and/or smoking reduction studies have never been investigated.

In this prospective proof-of-concept study we monitored modifications in smoking habits of 50 regular smokers (unwilling to quit) who were asked to switch to a second generation device focusing on smoking reduction and smoking abstinence. Study participants were invited to attend a total of five study visits: at baseline, week-4, week-8, week-12 and week-24. Product usage, number of cigarettes smoked, and exhaled carbon monoxide (eCO) levels were measured at each visit. Smoking reduction and abstinence rates were calculated. Adverse events and participants' opinions of these products were also reviewed.


Options:
A: Arm Label: Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Arm Label: No Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Intervention Type: BEHAVIORAL; Name: NH Medicaid Incentives Program; Assigned to Arm(s): Incentives, No Incentives
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation program TFC and activity tracker | Arm Label: Nicotine-free; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation program TFC-free and activity tracker | Arm Label: No-cig; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation program and activity tracker | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC and activity tracker; Assigned to Arm(s): Nicotine | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC-free and activity tracker; Assigned to Arm(s): Nicotine-free | Intervention Type: BEHAVIORAL; Name: Smoking cessation program and activity tracker; Assigned to Arm(s): No-cig
D: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Cessation Rates in Smokers Using Personal Vaporizers: A Prospective 6-month Pilot Study
Brief Summary: E-cigarettes are proving to be an attractive long-term alternative to conventional cigarettes. Although they may also help smokers to remain abstinent during their quit attempt, recent clinical trials with first generation e-cigarettes have shown only modest quit rates. Second generation devices may result in much higher quit rates. Their efficacy and safety in long-term smoking cessation and/or smoking reduction studies have never been investigated.

In this prospective proof-of-concept study we monitored modifications in smoking habits of 50 regular smokers (unwilling to quit) who were asked to switch to a second generation device focusing on smoking reduction and smoking abstinence. Study participants were invited to attend a total of five study visits: at baseline, week-4, week-8, week-12 and week-24. Product usage, number of cigarettes smoked, and exhaled carbon monoxide (eCO) levels were measured at each visit. Smoking reduction and abstinence rates were calculated. Adverse events and participants' opinions of these products were also reviewed.


Options:
A: Arm Label: Assessment Only (ASSESS); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Generic Self-Help (GENERIC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GENERIC | Arm Label: Targeted Self-Help (eTARGET); Type: EXPERIMENTAL; Interventions: Behavioral: eTARGET | Intervention Type: BEHAVIORAL; Name: GENERIC; Assigned to Arm(s): Generic Self-Help (GENERIC) | Intervention Type: BEHAVIORAL; Name: eTARGET; Assigned to Arm(s): Targeted Self-Help (eTARGET)
B: Arm Label: Electronic cigarettes; Type: EXPERIMENTAL; Interventions: Other: disposable electronic cigarettes | Intervention Type: OTHER; Name: disposable electronic cigarettes; Assigned to Arm(s): Electronic cigarettes
C: Arm Label: Standard Arm (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Other: TOBACCO CIGARETTES | Arm Label: Intervention Arm (Arm B); Type: ACTIVE_COMPARATOR; Interventions: Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS) | Intervention Type: OTHER; Name: TOBACCO CIGARETTES; Assigned to Arm(s): Standard Arm (Arm A) | Intervention Type: OTHER; Name: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS); Assigned to Arm(s): Intervention Arm (Arm B)
D: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Cessation Rates in Smokers Using Personal Vaporizers: A Prospective 6-month Pilot Study
Brief Summary: E-cigarettes are proving to be an attractive long-term alternative to conventional cigarettes. Although they may also help smokers to remain abstinent during their quit attempt, recent clinical trials with first generation e-cigarettes have shown only modest quit rates. Second generation devices may result in much higher quit rates. Their efficacy and safety in long-term smoking cessation and/or smoking reduction studies have never been investigated.

In this prospective proof-of-concept study we monitored modifications in smoking habits of 50 regular smokers (unwilling to quit) who were asked to switch to a second generation device focusing on smoking reduction and smoking abstinence. Study participants were invited to attend a total of five study visits: at baseline, week-4, week-8, week-12 and week-24. Product usage, number of cigarettes smoked, and exhaled carbon monoxide (eCO) levels were measured at each visit. Smoking reduction and abstinence rates were calculated. Adverse events and participants' opinions of these products were also reviewed.


Options:
A: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
B: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
C: Arm Label: Standard Arm (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Other: TOBACCO CIGARETTES | Arm Label: Intervention Arm (Arm B); Type: ACTIVE_COMPARATOR; Interventions: Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS) | Intervention Type: OTHER; Name: TOBACCO CIGARETTES; Assigned to Arm(s): Standard Arm (Arm A) | Intervention Type: OTHER; Name: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS); Assigned to Arm(s): Intervention Arm (Arm B)
D: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation program TFC and activity tracker | Arm Label: Nicotine-free; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation program TFC-free and activity tracker | Arm Label: No-cig; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation program and activity tracker | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC and activity tracker; Assigned to Arm(s): Nicotine | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC-free and activity tracker; Assigned to Arm(s): Nicotine-free | Intervention Type: BEHAVIORAL; Name: Smoking cessation program and activity tracker; Assigned to Arm(s): No-cig

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Cessation Rates in Smokers Using Personal Vaporizers: A Prospective 6-month Pilot Study
Brief Summary: E-cigarettes are proving to be an attractive long-term alternative to conventional cigarettes. Although they may also help smokers to remain abstinent during their quit attempt, recent clinical trials with first generation e-cigarettes have shown only modest quit rates. Second generation devices may result in much higher quit rates. Their efficacy and safety in long-term smoking cessation and/or smoking reduction studies have never been investigated.

In this prospective proof-of-concept study we monitored modifications in smoking habits of 50 regular smokers (unwilling to quit) who were asked to switch to a second generation device focusing on smoking reduction and smoking abstinence. Study participants were invited to attend a total of five study visits: at baseline, week-4, week-8, week-12 and week-24. Product usage, number of cigarettes smoked, and exhaled carbon monoxide (eCO) levels were measured at each visit. Smoking reduction and abstinence rates were calculated. Adverse events and participants' opinions of these products were also reviewed.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Brief Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: Extended Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Extended Treatment | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Treatment | Intervention Type: BEHAVIORAL; Name: Extended Treatment; Assigned to Arm(s): Extended Treatment | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
C: Arm Label: E-cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Traditional cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Mixed group; Type: N/A; Interventions: N/A
D: Arm Label: cigarette substitute; Type: EXPERIMENTAL; Interventions: Other: cigarette substitute | Arm Label: e-cigarette (with 0 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Arm Label: e-cigarette (with 8 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Arm Label: e-cigarette (with 36 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Intervention Type: OTHER; Name: e-cigarette; Assigned to Arm(s): e-cigarette (with 0 mg/ml nicotine), e-cigarette (with 36 mg/ml nicotine), e-cigarette (with 8 mg/ml nicotine) | Intervention Type: OTHER; Name: cigarette substitute; Assigned to Arm(s): cigarette substitute

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
Brief Summary: A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.


Options:
A: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: GSK1572932 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Control | Intervention Type: BIOLOGICAL; Name: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Assigned to Arm(s): GSK1572932 Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): Placebo Group
C: Arm Label: Tecemotide (L-BLP25); Type: EXPERIMENTAL; Interventions: Biological: Tecemotide (L-BLP25), Drug: Single low dose cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Tecemotide (L-BLP25); Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: MEDI4736; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Other: PLACEBO | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): MEDI4736 | Intervention Type: OTHER; Name: PLACEBO; Assigned to Arm(s): PLACEBO

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Brief Summary: Assessed the new film-coated tablet formulation to the currently approved dispersible tablet formulation with regards to overall safety, Gastrointestinal (GI) tolerability, palatability, satisfaction and compliance


Options:
A: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2
C: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)
D: Arm Label: Deferasirox dispersible tablet (DFX-DT); Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferasirox dispersible tablet | Arm Label: Deferasirox film-coated tablet (DFX-FCT); Type: EXPERIMENTAL; Interventions: Drug: Defearisox film-coated tablet | Intervention Type: DRUG; Name: Deferasirox dispersible tablet; Assigned to Arm(s): Deferasirox dispersible tablet (DFX-DT) | Intervention Type: DRUG; Name: Defearisox film-coated tablet; Assigned to Arm(s): Deferasirox film-coated tablet (DFX-FCT)

Answer: D